Robert J. Silverman

Cytyc Corp. manufactures and markets medical diagnostic applications. The company is headquartered in Marlborough, MA.

ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA.

Lightdeck Diagnostics engages in the development of clinical diagnostics and sample testing products. It offers the LightDeck platform, which consists of portable fluorescence analyzer and disposable, multiplex test cartridges. Its products are used in the medical, veterinary, environmental, food, agricultural, and military market segments. The company was founded by Christopher J. Myatt, Michael J. Lockhead, and Sarah C. Hatcher in 2009 and is headquartered in Boulder, CO.

KIYATEC, Inc. engages in the provision of biotechnology research services. The company was founded by Matthew R. Gevaert and David E. Orr in 2005 and is headquartered in Greenville, SC.

Microlin Bio, Inc. is a pre-clinical stage biopharmaceutical company. It focuses on the development of miR-based diagnostics and therapeutics, including both antimiRs and miR mimics, to diagnose and treat cancer. The company was founded by Joseph Hernandez on July 30, 2013 and is headquartered in New York, NY.

mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer.

Part of Cello Health Ltd., RS Consulting Group Ltd. specializes in market research and business consulting services. The company is based in London, UK. The British company was founded by Robert J. Silverman. RS Consulting Group was acquired by Cello Health Ltd. on August 01, 2005 for $8.41 million.